Pancragen
Also known as: Peptídeo pancreático
Molecular Identifiers
Overview
Pancreatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in pancreatic cells and supports beta cell function. Used in short cycles for pancreatic function protection and support.
Clinical interest in Pancragen centers on supporting endocrine and exocrine pancreatic tissue — particularly maintenance of beta-cell function and glycemic homeostasis. It is positioned as a bioregulatory peptide adjunct for pancreatic fatigue and mild metabolic dysfunction, not as a replacement for established diabetes therapies.
It has no drug approval from agencies such as the FDA, EMA, or ANVISA. It circulates through compounding pharmacies and specialty bioregulatory medicine channels, in short cycles of 10-20 days repeated 2-4 times per year, often combined with other Khavinson peptides in longitudinal protocols.
It belongs to the short cytogen line developed from the 1970s onward by the group led by Russian researcher Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. The evidence base is predominantly Russian, with modern human clinical trials still scarce.
Within the Khavinson family, Pancragen occupies the pancreatic niche: it differs from the other cytogens less by overall mechanism (tissue-specific gene expression regulation) and more by its proposed target — the beta cell and pancreatic tissue, as opposed to hepatic (livagen/ovagen) or cardiac (cardiogen). All of this comparative literature is largely Russian and preclinical.
KEDW Lys-Glu-Asp-Trp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in pancreatic cells
- Support for beta cell function and viability
- Normalization of insulin secretion
- Modulation of pancreatic glycemic metabolism
- Bioregulatory effect on endocrine and exocrine pancreas
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing AKS-P peptide complex) |
| Frequency | 1-2 times daily, before meals |
| Timing | Before meals |
| Duration | 1 month per cycle, repeat the course every 4-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Very stable tetrapeptide. Protect from light and moisture. |
Presentations & Preparation
Vials of Pancragen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Pancragen.
Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VKh
Effects of pancragen on the differentiation of pancreatic cells during their ageing
Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals